SPACInsider Logo
FS Development Corp. II (FSII) Shareholders Approve Pardes Biosciences Deal
by Kristi Marvin on 2021-12-23 at 11:32am

FS Development Corp. II (NASDAQ:FSII) filed an 8-K this morning revealing that its shareholders have approved its combination with antiviral drug developer firm Pardes Biosciences.

Just 243,989 shares, or 1.2%, were redeemed in connection with the vote, removing roughly $2.4 million from its estimated trust of $201 million. FSII did have a minimum cash closing condition of $100 million and a sponsor support agreement in place of up to $25 million in the event there was less than $25 million in trust post-redemptions. However, clearly it was not needed in this case. This was a good result at a time when “good votes” are hard to come by.

FS II hit highs of $14.97 late last month as excitement stirred about the potential applications of Pardes’ oral antiviral drug candidate PBI-0451 for use in combatting COVID-19 infections. It has since settled down near its pro rata trust value of $10.

The parties initially announced their $657 million combination on June 29. California-based Pardes is developing two antiviral drug candidates and PBI-0451 has been fast-tracked through the FDA approval process.

All measures on FS II’s ballot passed by wide margins. For full vote tallies, click here.


  • Jefferies LLC and SVB Leerink acted as co-lead private placement agents for, and financial and capital markets advisor to, FS Development Corp. II.
  • Goodwin Procter LLP acted as legal counsel to Pardes.
  • White & Case LLP acted as legal counsel to FS Development Corp. II.


Recent Posts
by Marlena Haddad on 2023-02-03 at 5:50pm

Forest Road II (NYSE:FRXB) and 10X Capital Venture III (NYSE:VCXB) both announced this afternoon that they have mutually terminated their business combinations. Forest Road II intended to combine with transportation technology developer HyperloopTT, but the parties decided to nix the deal due to timing constraints along with unfavorable market conditions. Tom Staggs and Kevin Mayer, Co-CEOs and...

by Marlena Haddad on 2023-02-03 at 5:30pm

Intelligent Medicine Acquisition Corp. (NASDAQ:IQMD) and AMCI Acquisition Corp. II (Nasdaq: AMCI) announced this afternoon that they have adjourned their special meetings with shareholders. Intelligent Medicine originally scheduled its meeting to be held today, but is now postponing its vote until Wednesday, February 8. Stockholders may elect to redeem their shares by no later than...

by Marlena Haddad on 2023-02-03 at 11:41am

  Below is a daily summary of links to the latest SPAC news and rumors gathered across the web.  Latest SPAC News: Comcast dumps 18.5% of its BuzzFeed stock Comcast Dumps 6 Million Shares of Buzzfeed After Media Company Finally Gets a Bump Comcast dumped 18.5% of its BuzzFeed (NASDAQ:BZFD) stock in recent days, reducing its...

by Nicholas Alan Clayton on 2023-02-03 at 11:37am

Viveon Health (NYSE:VHAQ) announced this morning that it is unilaterally terminating its combination with Suneva Medical “based upon material breaches” of the merger agreement. The SPAC did not elaborate further on its claims against Suneva, but noted it will continue on and seek a new business combination. Just last week, Viveon Health was working to...

by Nicholas Alan Clayton on 2023-02-03 at 9:49am

FAST II (NYSE:FZT) announced this morning that it has amended its combination with resort operator Falcon’s Beyond, shifting more value from both sides into earn-outs. The deal’s $1 billion enterprise value technically remains, but Falcon’s Beyond shareholders will receive less equity at close. The valuation is now made up of a $620 million enterprise value...

Privacy Policy|Terms Of Use
Copyright © 2023 SPACInsider, Inc. All Rights Reserved